Cardiotoxicity associated with targeting kinase pathways in cancer.

  title={Cardiotoxicity associated with targeting kinase pathways in cancer.},
  author={Howard R. Mellor and A. R. Bell and Jean-Pierre Valentin and R. Roberts},
  journal={Toxicological sciences : an official journal of the Society of Toxicology},
  volume={120 1},
  • Howard R. Mellor, A. R. Bell, +1 author R. Roberts
  • Published 2011
  • Medicine
  • Toxicological sciences : an official journal of the Society of Toxicology
  • Cardiotoxicity, also referred to as drug-induced cardiac injury, is an issue associated with the use of some small-molecule kinase inhibitors and antibody-based therapies targeting signaling pathways in cancer. Although these drugs have had a major impact on cancer patient survival, data have implicated kinase-targeting agents such as sunitinib, imatinib, trastuzumab, and sorafenib in adversely affecting cardiac function in a subset of treated individuals. In many cases, adverse cardiac events… CONTINUE READING


    Publications referenced by this paper.
    Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
    • 664
    • Highly Influential
    • PDF
    Cancer Therapy-Associated Cardiotoxicity and Signaling in the Myocardium
    • 29
    Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    • 876
    • Highly Influential
    • PDF
    Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
    • 994
    • Highly Influential
    • PDF
    An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
    • 145
    • PDF
    Pathogenesis of cardiotoxicity induced by anthracyclines.
    • 125
    Cardiotoxicity of cytotoxic drugs.
    • 333
    Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    • 345